Stroke is the fourth leading cause of death and the leading cause of long-term disability in the United States. Blood flow deficit results in an expanding infarct core with a time-sensitive peri-infarct penumbra that is considered salvageable and is the primary target for treatment strategies. The only current FDA-approved drug for treating ischemic stroke is recombinant tissue plasminogen activator (rt-PA). However, this treatment is limited to within 4.5 h of stroke onset in a small subset of patients. The goal of this review is to focus on mitochondrial-dependent therapeutic agents that could provide neuroprotection following stroke. Dysfunctional mitochondria are linked to neurodegeneration in many disease processes including stroke. The mechanisms reviewed include: (1) increasing ATP production by purinergic receptor stimulation, (2) decreasing the production of ROS by superoxide dismutase, or (3) increasing antioxidant defenses by methylene blue, and their benefits in providing neuroprotection following a stroke.
References
[1]
Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Adams, R.J.; Berry, J.D.; Brown, T.M.; Carnethon, M.R.; Dai, S.; de Simone, G.; Ford, E.S.; et al. Heart disease and stroke statistics—2011 update: A report from the American Heart Association. Circulation 2011, 123, e18–e209, doi:10.1161/CIR.0b013e3182009701.
[2]
Shang, W.; Liu, J. Stroke subtype classification: A comparative study of ASCO and modified TOAST. J. Neurol. Sci. 2012, 314, 66–70.
[3]
Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7, 41–53, doi:10.1038/nrn1824.
[4]
Globus, M.Y.; Busto, R.; Lin, B.; Schnippering, H.; Ginsberg, M.D. Detection of free radical activity during transient global ischemia and recirculation: Effects of intraischemic brain temperature modulation. J. Neurochem. 1995, 65, 1250–1256.
[5]
Sherman, D.G.; Easton, J.D. Cerebral edema in stroke: A common, often fatal complication. Postgrad. Med. 1980, 68, 107–113, 116, 119–120.
[6]
Brouns, R.; Wauters, A.; de Surgeloose, D.; Marien, P.; de Deyn, P.P. Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome. Eur. Neurol. 2011, 65, 23–31, doi:10.1159/000321965.
[7]
Hakim, A. The cerebral ischemic penumbra. Can. J. Neurol. Sci. 1987, 14, 557–559.
Soares, B.P.; Chien, J.D.; Wintermark, M. MR and CT Monitoring of Recanalization, Reperfusion, and Penumbra Salvage. Stroke 2009, 40, S24–S27.
[11]
Ferrer, I.; Planas, A.M. Signaling of cell death and cell survival following focal cerebral ischemia: Life and death struggle in the penumbra. J. Neuropathol. Exp. Neurol. 2003, 62, 329–339.
[12]
Wass, C.T.; Lanier, W.L. Glucose modulation of ischemic brain injury: Review and clinical recommendations. Mayo Clin. Proc. 1996, 71, 801–812, doi:10.1016/S0025-6196(11)64847-7.
[13]
Bruno, A.; Biller, J.; Adams, H.P., Jr.; Clarke, W.R.; Woolson, R.F.; Williams, L.S.; Hansen, M.D. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999, 52, 280–284, doi:10.1212/WNL.52.2.280.
[14]
Reith, J.; Jorgensen, H.S.; Pedersen, P.M.; Nakayama, H.; Raaschou, H.O.; Jeppesen, L.L.; Olsen, T.S. Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996, 347, 422–425.
[15]
Garcia, J.H.; Lassen, N.A.; Weiller, C.; Sperling, B.; Nakagawara, J. Ischemic stroke and incomplete infarction. Stroke 1996, 27, 761–765, doi:10.1161/01.STR.27.4.761.
[16]
Del Zoppo, G.J.; Pessin, M.S.; Mori, E.; Hacke, W. Thrombolytic intervention in acute thrombotic and embolic stroke. Semin. Neurol. 1991, 11, 368–384, doi:10.1055/s-2008-1041241.
[17]
Siesjo, B.K. Cell damage in the brain: A speculative synthesis. J. Cereb. Blood Flow Metab. 1981, 1, 155–185, doi:10.1038/jcbfm.1981.18.
[18]
Siesjo, B.K.; Agardh, C.D.; Bengtsson, F. Free radicals and brain damage. Cerebrovasc. Brain Metab. Rev. 1989, 1, 165–211.
[19]
Rothman, S.M.; Olney, J.W. Glutamate and the pathophysiology of hypoxic—ischemic brain damage. Ann. Neurol. 1986, 19, 105–111, doi:10.1002/ana.410190202.
DeGraba, T.J. The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy. Neurology 1998, 51, S62–S68, doi:10.1212/WNL.51.3_Suppl_3.S62.
[23]
Kroemer, G.; Petit, P.; Zamzami, N.; Vayssiere, J.L.; Mignotte, B. The biochemistry of programmed cell death. FASEB J. 1995, 9, 1277–1287.
[24]
Garcia, J.H.; Liu, K.-F.; Ho, K.-L. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the audoputamen and the cortex. Stroke 1995, 26, 636–643, doi:10.1161/01.STR.26.4.636.
[25]
Davis, S.M.; Donnan, G.A. 4.5 hours: The new time window for tissue plasminogen activator in stroke. Stroke 2009, 40, 2266–2267, doi:10.1161/STROKEAHA.108.544171.
[26]
Kleindorfer, D.; Kissela, B.; Schneider, A.; Woo, D.; Khoury, J.; Miller, R.; Alwell, K.; Gebel, J.; Szaflarski, J.; Pancioli, A.; et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. Stroke 2004, 35, e27–e29, doi:10.1161/01.STR.0000109767.11426.17.
[27]
Crumrine, R.C.; Marder, V.J.; Taylor, G.M.; Lamanna, J.C.; Tsipis, C.P.; Scuderi, P.; Petteway, S.R., Jr.; Arora, V. Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model. Exp. Transl. Stroke Med. 2011, 3, 10, doi:10.1186/2040-7378-3-10.
[28]
Hacke, W.; Donnan, G.; Fieschi, C.; Kaste, M.; von Kummer, R.; Broderick, J.P.; Brott, T.; Frankel, M.; Grotta, J.C.; Haley, E.C., Jr.; et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363, 768–774, doi:10.1016/S0140-6736(04)15692-4.
[29]
Wahlgren, N.; Ahmed, N.; Davalos, A.; Ford, G.A.; Grond, M.; Hacke, W.; Hennerici, M.G.; Kaste, M.; Kuelkens, S.; Larrue, V.; et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 2007, 369, 275–282.
[30]
Suzuki, S.; Saver, J.L.; Scott, P.; Jahan, R.; Duckwiler, G.; Starkman, S.; Su, Y.; Kidwell, C.S. Access to intra-arterial therapies for acute ischemic stroke: An analysis of the US population. AJNR Am. J. Neuroradiol. 2004, 25, 1802–1806.
[31]
Chih, C.P.; Roberts, E.L. Energy substrates for neurons during neural activity: A critical review of the astrocyte-neuron lactate shuttle hypothesis. J. Cereb. Blood Flow Metab. 2003, 23, 1263–1281, doi:10.1097/01.WCB.0000081369.51727.6F.
[32]
Swanson, R.A.; Benington, J. Astrocyte glucose metabolism under normal and pathological conditions in vitro. Dev. Neurosci. 1996, 18, 515–521, doi:10.1159/000111448.
[33]
Swanson, R.A.; Yu, A.C.H.; Sharp, F.R.; Chan, P.H. Regulation of glycogen content in primary astrocyte culture: Effects of glucose analogues, phenobarbital, and methionine sulfoximine. J. Neurochem. 1989, 52, 1359–1365, doi:10.1111/j.1471-4159.1989.tb09180.x.
[34]
Detmer, S.A.; Chan, D.C. Functions and dysfunctions of mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 2007, 8, 870–879, doi:10.1038/nrm2275.
[35]
Sies, H. Oxidative stress: From basic research to clinical application. Am. J. Med. 1991, 91, S31–S38, doi:10.1016/0002-9343(91)90281-2.
[36]
Balaban, R.S.; Nemoto, S.; Finkel, T. Mitochondria, oxidants, and aging. Cell 2005, 120, 483–495, doi:10.1016/j.cell.2005.02.001.
[37]
Brookes, P.S. Mitochondrial H+ leak and ROS generation: An odd couple. Free Radic. Biol. Med. 2005, 38, 12–23, doi:10.1016/j.freeradbiomed.2004.10.016.
[38]
Nohl, H.; Gille, L.; Staniek, K. Intracellular generation of reactive oxygen species by mitochondria. Biochem. Pharmacol. 2005, 69, 719–723.
Raha, S.; Robinson, B.H. Mitochondria, oxygen free radicals, and apoptosis. Am. J. Med. Genet. 2001, 106, 62–70, doi:10.1002/ajmg.1398.
[41]
Pastorino, J.G.; Snyder, J.W.; Serroni, A.; Hoek, J.B.; Farber, J.L. Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J. Biol. Chem. 1993, 268, 13791–13798.
[42]
Zahrebelski, G.; Nieminen, A.L.; Al-Ghoul, K.; Qian, T.; Herman, B.; Lemasters, J.J. Progression of subcellular changes during chemical hypoxia to cultured rat hepatocytes: A laser scanning confocal microscopic study. Hepatology 1995, 21, 1361–1372.
[43]
Beal, M.F.; Brouillet, E.; Jenkins, B.G.; Ferrante, R.J.; Kowall, N.W.; Miller, J.M.; Storey, E.; Srivastava, R.; Rosen, B.R.; Hyman, B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13, 4181–4192.
[44]
Dawson, T.L.; Gores, G.J.; Nieminen, A.L.; Herman, B.; Lemasters, J.J. Mitochondria as a source of reactive oxygen species during reductive stress in rat hepatocytes. Am. J. Physiol. 1993, 264, C961–C967.
[45]
Newmeyer, D.D.; Farschon, D.M.; Reed, J.C. Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994, 79, 353–364, doi:10.1016/0092-8674(94)90203-8.
[46]
Zamzami, N.; Susin, S.A.; Marchetti, P.; Hirsch, T.; Gomez-Monterrey, I.; Castedo, M.; Kroemer, G. Mitochondrial control of nuclear apoptosis. J. Exp. Med. 1996, 183, 1533–1544.
[47]
Petit, P.X.; Lecoeur, H.; Zorn, E.; Dauguet, C.; Mignotte, B.; Gougeon, M.L. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J. Cell Biol. 1995, 130, 157–167, doi:10.1083/jcb.130.1.157.
[48]
Kroemer, G. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution. Cell Death Differ. 1997, 4, 443–456.
[49]
Chan, K.; Han, X.D.; Kan, Y.W. An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen. Proc. Natl. Acad. Sci. USA 2001, 98, 4611–4616, doi:10.1073/pnas.081082098.
[50]
Sawada, M.; Sester, U.; Carlson, J.C. Superoxide radical formation and associated biochemical alterations in the plasma membrane of brain, heart, and liver during the lifetime of the rat. J. Cell. Biochem. 1992, 48, 296–304.
[51]
Antier, D.; Carswell, H.V.; Brosnan, M.J.; Hamilton, C.A.; Macrae, I.M.; Groves, S.; Jardine, E.; Reid, J.L.; Dominiczak, A.E. Increased levels of superoxide in brains from old female rats. Free Radic. Res. 2004, 38, 177–183.
[52]
Dienel, G.A.; Hertz, L. Astrocytic contributions to bioenergetics of cerebral ischemia. Glia 2005, 50, 362–388.
[53]
Bernardi, M.L.; Flechon, J.E.; Delouis, C. Influence of culture system and oxygen tension on the development of ovine zygotes matured and fertilized in vitro. J. Reprod. Fertil. 1996, 106, 161–167, doi:10.1530/jrf.0.1060161.
[54]
Bains, J.S.; Shaw, C.A. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 1997, 25, 335–358.
[55]
Robb, S.J.; Connor, J.R. An in vitro model for analysis of oxidative death in primary mouse astrocytes. Brain Res. 1998, 788, 125–132, doi:10.1016/S0006-8993(97)01543-6.
[56]
Amin, N.; Pearce, B. Glutamate toxicity in neuron-enriched and neuron-astrocyte co-cultures: Effect of the glutamate uptake inhibitor l-trans-pyrrolidine-2,4-dicarboxylate. Neurochem. Int. 1997, 30, 271–276, doi:10.1016/S0197-0186(96)00092-7.
[57]
Winn, H.R.; Rubio, R.; Berne, R.M. Brain adenosine production in the rat during 60 seconds of ischemia. Circ. Res. 1979, 45, 486–492, doi:10.1161/01.RES.45.4.486.
[58]
Schultz, S.G. Pump-leak parallelism in sodium-absorbing epithelia: The role of ATP-regulated potassium channels. J. Exp. Zool. 1997, 279, 476–483, doi:10.1002/(SICI)1097-010X(19971201)279:5<476::AID-JEZ10>3.0.CO;2-6.
[59]
Liu, S.; Levine, S.R.; Winn, H.R. Targeting ischemic penumbra: Part I—from pathophysiology to therapeutic strategy. J. Exp. Stroke Transl. Med. 2010, 3, 47–55, doi:10.6030/1939-067X-3.1.47.
[60]
Abbracchio, M.P.; Burnstock, G. Purinergic signalling: Pathophysiological roles. Jpn. J. Pharmacol. 1998, 78, 113–145, doi:10.1254/jjp.78.113.
[61]
Fredholm, B.B. Purinoceptors in the nervous system. Pharmacol. Toxicol. 1995, 76, 228–239, doi:10.1111/j.1600-0773.1995.tb00135.x.
Rudolphi, K.A.; Schubert, P.; Parkinson, F.E.; Fredholm, B.B. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 1992, 13, 439–445.
[64]
Williams, M.; Burnstock, G. Purinergic Neurotransmission and Neuromodulation: A Historical Perspective; Wiley-Liss: New York, NY, USA, 1997.
[65]
Winn, H.R.; Rubio, G.R.; Berne, R.M. The role of adenosine in the regulation of cerebral blood flow. J. Cereb. Blood Flow Metab. 1981, 1, 239–244, doi:10.1038/jcbfm.1981.29.
[66]
Zhou, G.; Smith, J.L.; Zalkin, H. Binding of purine nucleotides to two regulatory sites results in synergistic feedback inhibition of glutamine 5-phosphoribosylpyrophosphate amidotransferase. J. Biol. Chem. 1994, 269, 6784–6789.
[67]
Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50, 413–492.
[68]
Verkhratsky, A.; Kettenmann, H. Calcium signalling in glial cells. Trends Neurosci. 1996, 19, 346–352, doi:10.1016/0166-2236(96)10048-5.
[69]
James, G.; Butt, A.M. P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell pathology in the central nervous system. Eur. J. Pharmacol. 2002, 447, 247–260, doi:10.1016/S0014-2999(02)01756-9.
[70]
Denton, R.M.; McCormack, J.G. Physiological role of Ca2+ transport by mitochondria. Nature 1985, 315, 635, doi:10.1038/315635a0.
[71]
McCormack, J.G.; Halestrap, A.P.; Denton, R.M. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol. Rev. 1990, 70, 391–425.
[72]
Hajnoczky, G.; Csordas, G.; Krishnamurthy, R.; Szalai, G. Mitochondrial calcium signaling driven by the IP3 receptor. J. Bioenerg. Biomembr. 2000, 32, 15–25, doi:10.1023/A:1005504210587.
[73]
Hajnoczky, G.; Robb-Gaspers, L.D.; Seitz, M.B.; Thomas, A.P. Decoding of cytosolic calcium oscillations in the mitochondria. Cell 1995, 82, 415–424, doi:10.1016/0092-8674(95)90430-1.
[74]
Sak, K.; Webb, T.E. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch. Biochem. Biophys. 2002, 397, 131–136, doi:10.1006/abbi.2001.2616.
[75]
Burnstock, G. P2X receptors in sensory neurones. Br. J. Anaesth. 2000, 84, 476–488.
[76]
Burnstock, G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007, 87, 659–797.
[77]
Fabre, J.E.; Nguyen, M.; Latour, A.; Keifer, J.A.; Audoly, L.P.; Coffman, T.M.; Koller, B.H. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat. Med. 1999, 5, 1199–1202.
[78]
Leon, C.; Hechler, B.; Freund, M.; Eckly, A.; Vial, C.; Ohlmann, P.; Dierich, A.; LeMeur, M.; Cazenave, J.P.; Gachet, C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J. Clin. Invest. 1999, 104, 1731–1737.
[79]
Wu, O.; Sumii, T.; Asahi, M.; Sasamata, M.; Ostergaard, L.; Rosen, B.R.; Lo, E.H.; Dijkhuizen, R.M. Infarct prediction and treatment assessment with MRI-based algorithms in experimental stroke models. J. Cereb. Blood Flow Metab. 2007, 27, 196–204.
[80]
Zheng, W.; Watts, L.T.; Holstein, D.M.; Prajapati, S.I.; Keller, C.; Grass, E.H.; Walter, C.A.; Lechleiter, J.D. Purinergic receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by photothrombosis by energizing glial mitochondria. PLos One 2010, 5, e14401.
[81]
Zheng, W.; Talley Watts, L.; Holstein, D.M.; Wewer, J.; Lechleiter, J.D. P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. J. Cereb. Blood Flow Metab. 2012, 33, 600–611.
[82]
Owens, A.P., III; Mackman, N. Tissue factor and thrombosis: The clot starts here. Thromb. Haemost. 2010, 104, 432–439, doi:10.1160/TH09-11-0771.
Savi, P.; Beauverger, P.; Labouret, C.; Delfaud, M.; Salel, V.; Kaghad, M.; Herbert, J.M. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998, 422, 291–295, doi:10.1016/S0014-5793(98)00025-8.
[85]
Jin, J.; Daniel, J.L.; Kunapuli, S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 1998, 273, 2030–2034, doi:10.1074/jbc.273.4.2030.
[86]
Jin, J.; Kunapuli, S.P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. USA 1998, 95, 8070–8074, doi:10.1073/pnas.95.14.8070.
[87]
Hechler, B.; Leon, C.; Vial, C.; Vigne, P.; Frelin, C.; Cazenave, J.P.; Gachet, C. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998, 92, 152–159.
[88]
Jarvis, G.E.; Humphries, R.G.; Robertson, M.J.; Leff, P. ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors. Br. J. Pharmacol. 2000, 129, 275–282, doi:10.1038/sj.bjp.0703046.
[89]
Chhatriwala, M.; Ravi, R.G.; Patel, R.I.; Boyer, J.L.; Jacobson, K.A.; Harden, T.K. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J. Pharmacol. Exp. Ther. 2004, 311, 1038–1043, doi:10.1124/jpet.104.068650.
[90]
Ravi, R.G.; Kim, H.S.; Servos, J.; Zimmermann, H.; Lee, K.; Maddileti, S.; Boyer, J.L.; Harden, T.K.; Jacobson, K.A. Adenine nucleotide analogues locked in a Northern methanocarba conformation: Enhanced stability and potency as P2Y(1) receptor agonists. J. Med. Chem. 2002, 45, 2090–2100.
[91]
Lu, M.; Zhang, R.L.; Zhang, Z.G.; Yang, J.J.; Chopp, M. Linkage of cell cycle kinetics between embryonic and adult stroke models: An analytical approach. J. Neurosci. Methods 2007, 161, 323–330, doi:10.1016/j.jneumeth.2006.10.021.
[92]
Cavaliere, F.; Florenzano, F.; Amadio, S.; Fusco, F.R.; Viscomi, M.T.; D’Ambrosi, N.; Vacca, F.; Sancesario, G.; Bernardi, G.; Molinari, M.; Volonte, C. Up-regulation of P2X2, P2X4 receptor and ischemic cell death: prevention by P2 antagonists. Neuroscience 2003, 120, 85–98, doi:10.1016/S0306-4522(03)00228-8.
[93]
Rojas, J.C.; Bruchey, A.K.; Gonzalez-Lima, F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog. Neurobiol. 2012, 96, 32–45, doi:10.1016/j.pneurobio.2011.10.007.
[94]
Guttmann, P.; Ehrlich, P. ber die Wirkung des Methylenblau bei Malaria. Berl. Klin. Wochenschr. 1891, 28, 953–956.
[95]
Kupfer, A.; Aeschlimann, C.; Cerny, T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur. J. Clin. Pharmacol. 1996, 50, 249–252, doi:10.1007/s002280050102.
[96]
Wainwright, M.; Crossley, K.B. Methylene Blue—A therapeutic dye for all seasons? J. Chemother. 2002, 14, 431–443.
[97]
Naylor, G.J.; Martin, B.; Hopwood, S.E.; Watson, Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol. Psychiatry 1986, 21, 915–920, doi:10.1016/0006-3223(86)90265-9.
[98]
Zhang, X.; Rojas, J.C.; Gonzalez-Lima, F. Methylene blue prevents neurodegeneration caused by rotenone in the retina. Neurotox. Res. 2006, 9, 47–57, doi:10.1007/BF03033307.
[99]
Peter, C.; Hongwan, D.; Kupfer, A.; Lauterburg, B.H. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur. J. Clin. Pharmacol. 2000, 56, 247–250, doi:10.1007/s002280000124.
[100]
Oz, M.; Lorke, D.E.; Petroianu, G.A. Methylene blue and Alzheimer’s disease. Biochem. Pharmacol. 2009, 78, 927–932.
[101]
Wiklund, L.; Basu, S.; Miclescu, A.; Wiklund, P.; Ronquist, G.; Sharma, H.S. Neuro- and cardioprotective effects of blockade of nitric oxide action by administration of methylene blue. Ann. N. Y. Acad. Sci. 2007, 1122, 231–244.
[102]
Miclescu, A.; Basu, S.; Wiklund, L. Cardio-cerebral and metabolic effects of methylene blue in hypertonic sodium lactate during experimental cardiopulmonary resuscitation. Resuscitation 2007, 75, 88–97, doi:10.1016/j.resuscitation.2007.03.014.
[103]
Kelner, M.J.; Bagnell, R.; Hale, B.; Alexander, N.M. Potential of methylene blue to block oxygen radical generation in reperfusion injury. Basic Life Sci. 1988, 49, 895–898.
[104]
Miclescu, A.; Basu, S.; Wiklund, L. Methylene blue added to a hypertonic-hyperoncotic solution increases short-term survival in experimental cardiac arrest. Crit. Care Med. 2006, 34, 2806–2813, doi:10.1097/01.CCM.0000242517.23324.27.
[105]
Wen, Y.; Li, W.; Poteet, E.C.; Xie, L.; Tan, C.; Yan, L.J.; Ju, X.; Liu, R.; Qian, H.; Marvin, M.A.; et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J. Biol. Chem. 2011, 286, 16504–16515, doi:10.1074/jbc.M110.208447.
[106]
Lin, A.L.; Poteet, E.; Du, F.; Gourav, R.C.; Liu, R.; Wen, Y.; Bresnen, A.; Huang, S.; Fox, P.T.; Yang, S.H.; Duong, T.Q. Methylene blue as a cerebral metabolic and hemodynamic enhancer. Plos One 2012, 7, e46585.
[107]
Huang, S.; Du, F.; Shih, Y.I.; Shen, Q.; Gonzalez-Lima, F.; Duong, T.Q. Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. NeuroImage 2013, 72, 237–242, doi:10.1016/j.neuroimage.2013.01.027.
[108]
Devasagayam, T.P.; Tilak, J.C.; Boloor, K.K.; Sane, K.S.; Ghaskadbi, S.S.; Lele, R.D. Free radicals and antioxidants in human health: Current status and future prospects. J. Assoc. Physicians India 2004, 52, 794–804.
[109]
Holley, A.K.; Bakthavatchalu, V.; Velez-Roman, J.M.; St Clair, D.K. Manganese superoxide dismutase: Guardian of the powerhouse. Int. J. Mol. Sci. 2011, 12, 7114–7162, doi:10.3390/ijms12107114.
[110]
Niizuma, K.; Endo, H.; Chan, P.H. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J. Neurochem. 2009, 109 (Suppl. 1), 133–138, doi:10.1111/j.1471-4159.2009.05897.x.
[111]
Holley, A.K.; Dhar, S.K.; St Clair, D.K. Manganese superoxide dismutase vs. p53: Regulation of mitochondrial ROS. Mitochondrion 2010, 10, 649–661, doi:10.1016/j.mito.2010.06.003.
[112]
Shmonin, A.; Melnikova, E.; Galagudza, M.; Vlasov, T. Characteristics of cerebral ischemia in major rat stroke models of middle cerebral artery ligation through craniectomy. Int. J. Stroke 2012, doi:10.1111/j.1747-4949.2012.00947.x.
[113]
Maier, C.M.; Hsieh, L.; Crandall, T.; Narasimhan, P.; Chan, P.H. A new approach for the investigation of reperfusion-related brain injury. Biochem. Soc. Trans. 2006, 34, 1366–1369, doi:10.1042/BST0341366.
[114]
Ivanovi-Burmazovi？, I.; Filipovi？, M. Reactivity of manganese superoxide dismutase mimics toward superoxide and nitric oxide: Selectivity versus cross-reactivity. Adv.Inorg. Chem. 2012, 64, 53–95, doi:10.1016/B978-0-12-396462-5.00003-9.
[115]
Friedel, F.C.; Lieb, D.; Ivanovi？-Burmazovi？, I. Comparative studies on manganese-based SOD mimetics, including the phosphate effect, by using global spectral analysis. J. Inorg. Biochem. 2012, 109, 26–32, doi:10.1016/j.jinorgbio.2011.12.008.
[116]
Park, W.; Lim, D. Synthesis and SOD activity of manganese complexes of pentaaza macrocycles containing amino- and guanidino-auxiliary. Bull. Korean Chem. Soc. 2001, 32, 3787.
Shen, Q.; Fisher, M.; Sotak, C.H.; Duong, T.Q. Effects of reperfusion on ADC and CBF pixel-by-pixel dynamics in stroke: Characterizing tissue fates using quantitative diffusion and perfusion imaging. J. Cereb. Blood Flow Metab. 2004, 24, 280–290.
[120]
Shen, Q.; Huang, S.; Du, F.; Duong, T.Q. Probing ischemic tissue fate with bold fMRI of brief oxygen challenge. Brain Res. 2011, 1425, 132–141.
[121]
Shen, Q.; Meng, X.; Fisher, M.; Sotak, C.H.; Duong, T.Q. Pixel-by-pixel spatiotemporal progression of focal ischemia derived using quantitative perfusion and diffusion imaging. J.Cereb. BloodFlow Metab. 2003, 23, 1479–1488.
[122]
Shen, Q.; Ren, H.; Cheng, H.; Fisher, M.; Duong, T.Q. Functional, perfusion and diffusion MRI of acute focal ischemic brain injury. J. Cereb. Blood Flow Metab. 2005, 25, 1265–1279.
[123]
Meng, X.; Fisher, M.; Shen, Q.; Sotak, C.H.; Duong, T.Q. Characterizing the diffusion/perfusion mismatch in experimental focal cerebral ischemia. Ann. Neurol. 2004, 55, 207–212, doi:10.1002/ana.10803.
[124]
Hui, E.S.; Du, F.; Huang, S.; Shen, Q.; Duong, T.Q. Spatiotemporal dynamics of diffusional kurtosis, mean diffusivity and perfusion changes in experimental stroke. Brain Res. 2012, 1451, 100–109.
[125]
Sicard, K.M.; Henninger, N.; Fisher, M.; Duong, T.Q.; Ferris, C.F. Long-term changes of functional MRI based brain function, behavioral status, and histopathology after transient focal cerebral ischemia in rats. Stroke 2006, 37, 2593–2600, doi:10.1161/01.STR.0000239667.15532.c1.
[126]
Sicard, K.M.; Henninger, N.; Fisher, M.; Duong, T.Q.; Ferris, C.F. Differential recovery of multimodal mri and behavior after transient focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 2006, 26, 1451–1462, doi:10.1038/sj.jcbfm.9600299.
[127]
Tanaka, Y.; Ishii, H.; Hiraoka, M.; Miyasaka, N.; Kuroiwa, T.; Hajjar, K.A.; Nagaoka, T.; Duong, T.Q.; Ohno, K.; Yoshida, M. Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: A magnetic resonance imaging study. Brain Res. 2007, 1165, 135–143.
[128]
Shen, Q.; Ren, H.; Fisher, M.; Bouley, J.; Duong, T.Q. Dynamic tracking of acute ischemic tissue fates using improved unsupervised isodata analysis of high-resolution quantitative perfusion and diffusion data. J. Cereb. Blood Flow Metab. 2004, 24, 887–897.
[129]
Shen, Q.; Ren, H.; Fisher, M.; Duong, T.Q. Statistical prediction of tissue fate in acute ischemic brain injury. J. Cereb. Blood Flow Metab. 2005, 25, 1336–1345, doi:10.1038/sj.jcbfm.9600126.
[130]
Huang, S.; Shen, Q.; Duong, T.Q. Artificial neural network prediction of ischemic tissue fate in acute stroke imaging. J. Cereb. Blood Flow Metab. 2010, 30, 1661–1670, doi:10.1038/jcbfm.2010.56.
[131]
Huang, S.; Shen, Q.; Duong, T.Q. Quantitative prediction of acute ischemic tissue fate using support vector machine. Brain Res. 2011, 1045, 77–84.
